{"gene":"APOA5","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2021,"finding":"ApoA5 lowers triglycerides by binding to the ANGPTL3/8 complex in human serum and suppressing ANGPTL3/8-mediated inhibition of lipoprotein lipase (LPL); ApoA5 has no direct stimulatory effect on LPL itself, nor does it suppress LPL inhibition by ANGPTL3, ANGPTL4, or ANGPTL4/8 alone.","method":"Immunoprecipitation-MS, Western blotting, biolayer interferometry, functional LPL enzymatic assays, kinetic analyses","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (IP-MS, biolayer interferometry, LPL activity assays) in a single rigorous study with both positive and negative controls; mechanistically conclusive","pmids":["33762177"],"is_preprint":false},{"year":2024,"finding":"APOA5 C-terminal sequences (last ~35-40 residues) are required for binding ANGPTL3/8, suppressing ANGPTL3/8-mediated inhibition of LPL catalytic activity, blocking ANGPTL3/8-mediated detachment of LPL from capillary binding sites, maintaining intracapillary LPL levels in oxidative tissues, and lowering plasma triglycerides in vivo; a truncation mutant lacking these residues (APOA5Δ40) fails at all these functions.","method":"Recombinant protein functional assays, LPL activity assays, Apoa5-/- mouse rescue experiments, anti-APOA5 C-terminal antibody injection in WT mice, cell culture LPL detachment assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal in vitro and in vivo experiments with domain-mapping mutagenesis (truncation mutant) and antibody blockade, replicated across cell and animal models","pmids":["38625948"],"is_preprint":false},{"year":2024,"finding":"APOA5 deficiency reduces amounts of LPL in capillaries of oxidative tissues (heart, brown adipose tissue) through increased ANGPTL3/8-mediated detachment of LPL from its binding sites; recombinant APOA5 normalizes both intracapillary LPL levels and plasma triglycerides in Apoa5-/- mice, and an ANGPTL3/8-specific inhibitory antibody phenocopies APOA5 function.","method":"Apoa5-/- mouse model, recombinant APOA5 administration, ANGPTL3/8 inhibitory antibody treatment, cell culture LPL binding/detachment assays","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo rescue experiments with recombinant protein plus mechanistic cell culture validation, consistent with PMID 38625948","pmids":["38880127"],"is_preprint":false},{"year":2005,"finding":"The APOA5 S19W (c.56C>G) polymorphism impairs secretion of apoA-V: molecular modeling predicts increased membrane insertion angle for Trp-19 signal peptide, and an in vitro secretion assay using SP-SEAP fusion proteins in HepG2 cells showed ~50% reduction in secretion of the Trp-19 encoded signal peptide compared to Ser-19.","method":"Molecular modeling of signal peptide, SP-SEAP fusion protein secretion assay in HepG2 cells, in vitro transcription/translation assay, primer extension inhibition assay, luciferase reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro functional secretion assay with mechanistic modeling, single lab, but multiple complementary methods; in vivo validation later confirmed by PMID 17936576","pmids":["15941721"],"is_preprint":false},{"year":2007,"finding":"The S19W (APOA5*3) haplotype-defining polymorphism is functionally responsible for reduced plasma apoA-V levels: knock-in of the single APOA5*3 allele (19W) at the mouse Hprt locus resulted in three-fold lower human plasma ApoA-V levels compared to common APOA5*1 haplotype, while APOA5*2 showed no difference in plasma apoA-V.","method":"Targeted single-copy haplotype insertion at Hprt locus in mice, plasma apoA-V measurement","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean in vivo knock-in experiment with precise genetic control, single lab, directly confirms S19W as causative functional variant","pmids":["17936576"],"is_preprint":false},{"year":2005,"finding":"APOA5 Q139X truncation mutation impairs VLDL catabolism and reduces lipoprotein lipase activity and mass in carriers; the truncated apoA-V protein shows altered association with plasma lipoprotein fractions compared to wild-type apoA-V. APOB100 kinetic studies revealed major impairment of VLDL catabolism in dyslipidemic Q139X carriers.","method":"Family/pedigree study, ultracentrifugation lipoprotein fractionation, APOB100 kinetic studies, postheparin LPL activity and mass measurement","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo human kinetic studies with multiple complementary measurements; mechanistically links APOA5 truncation to defective lipolysis","pmids":["16200213"],"is_preprint":false},{"year":2008,"finding":"Specific APOA5 missense variants (E255G, G185C, H321L) reduce LPL activation using VLDL as substrate in vitro (by 23-36%), while truncation variants (Q139X, Q148X) and G271C show no significant reduction in LPL activity but abolish binding to LDL-family receptors LR8 and LRP1.","method":"In vitro LPL activity assay using VLDL substrate, receptor-binding assay to LR8 and LRP1 with recombinant apoA-V variants","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple defined mutants, single lab, demonstrates separable LPL-activation and receptor-binding functions","pmids":["18635818"],"is_preprint":false},{"year":2013,"finding":"Three APOA5 mutations [p.(Ser232_Leu235)del, p.Leu253Pro, p.Asp332ValfsX4] impair LPL activation in vitro; recombinant mutant apoA-V variants show defective interactions with liposomes, heparin, LRP1, sortilin, and SorLA/LR11 compared to wild-type, indicating multiple functional domains are affected.","method":"Recombinant protein expression and purification, LPL activation assay, liposome binding, heparin binding, LRP1/sortilin/SorLA receptor binding assays, 3D structural modeling","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple orthogonal binding and activity assays, single lab","pmids":["23307945"],"is_preprint":false},{"year":2014,"finding":"The APOA5 c.553G>T (rs2075291, p.Gly185Cys) variant introduces a free cysteine that forms aberrant hetero-disulfide bonds with plasma proteins (fibronectin, kininogen-1, and others), sequestering >50% of G162C apoA-V in the lipoprotein-free fraction and compromising its lipoprotein-binding and triglyceride-modulating functions.","method":"AAV2/8-mediated gene transfer in apoa5-/- mice, plasma fractionation, nonreducing SDS-PAGE immunoblot, immunoprecipitation followed by LC/MS of human plasma from homozygous subjects","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo gene transfer rescue, biochemical fractionation, mass spectrometry identification of aberrant disulfide partners in both mouse model and human plasma; multiple orthogonal methods","pmids":["25127531"],"is_preprint":false},{"year":2005,"finding":"Thyroid hormone T3 directly regulates APOA5 expression in hepatocytes via a DR4 thyroid hormone response element in the APOA5 promoter; T3-activated thyroid receptor (TR) acts synergistically with USF1 and USF2 via an adjacent E-box motif to activate APOA5 promoter in a ligand-dependent manner.","method":"Luciferase reporter assays in hepatocytes, APOA5 mRNA/protein measurement in T3-treated and hypothyroid rats, TRbeta-selective agonist treatment, promoter deletion/mutation analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct promoter functional assay with in vivo validation in rat model, single lab, multiple methods","pmids":["15941710"],"is_preprint":false},{"year":2014,"finding":"The APOA5 3'UTR variant c.*158C (rs2266788) creates a functional binding site for liver-expressed miR-485-5p, leading to post-transcriptional downregulation of APOA5 mRNA; reporter assays and miR-485-5p inhibitor rescue confirmed this mechanism as a basis for the hypertriglyceridemic effect of the APOA5*2 haplotype.","method":"Luciferase reporter assay with APOA5 3'UTR in HEK293T and HuH-7 cells, miR-485-5p precursor co-transfection, miR-485-5p inhibitor rescue experiment, bioinformatics","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assay with inhibitor rescue in two cell lines, single lab, mechanistically specific","pmids":["24387992"],"is_preprint":false},{"year":2018,"finding":"APOA5 expression is regulated by the transcription factor CREBH in response to dietary protein restriction; PR stimulates VLDL-TG clearance by increasing VLDL-bound APOA5 expression, an effect abrogated by constitutive hepatic mTORC1 activation. This CREBH-APOA5 axis was conserved in a human clinical trial showing reduced VLDL particle number and increased VLDL-bound APOA5 upon protein restriction.","method":"Protein-free diet mouse model, Crebh-knockout mice, mTORC1 gain-of-function mice, ASO-mediated knockdown, VLDL-TG clearance assays, randomized controlled clinical trial","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with Crebh KO and mTORC1 GOF mice plus human translational validation, single lab","pmids":["30385734"],"is_preprint":false},{"year":2007,"finding":"ApoA-V reduces apoC-III content in VLDL, resulting in enhanced VLDL catabolism without altering VLDL production; apoA-V also enriches HDL with apoA-I and apoE, enhances LCAT activity, and increases cholesterol efflux, promoting HDL maturation in APOC3 transgenic mice.","method":"Adenovirus-mediated apoA-V gene transfer into APOC3 transgenic mice, plasma TG/cholesterol measurement, lipoprotein fractionation, LCAT activity assay, cholesterol efflux assay","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gene transfer with multiple functional readouts in a defined transgenic model, single lab","pmids":["17438339"],"is_preprint":false},{"year":2014,"finding":"ApoA5 knockdown in high-fat-diet mice (via ASO reducing hepatic ApoA5 by 60-70%) reduces TG uptake in liver and skeletal muscle, decreasing diacylglycerol content and DAG-mediated activation of PKCε (liver) and PKCθ (muscle), thereby protecting against diet-induced insulin resistance as assessed by hyperinsulinemic-euglycemic clamps.","method":"Antisense oligonucleotide knockdown in mice, VLDL-TG clearance assays, hyperinsulinemic-euglycemic clamp, PKC activity measurement, AKT2 phosphorylation assay, tissue TG/DAG measurement","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic KD with multiple mechanistic readouts in vivo, single lab, novel pathway placement","pmids":["25548259"],"is_preprint":false},{"year":2020,"finding":"Proprotein convertase PC7 (PCSK7) binds to apoA-V and promotes its degradation in acidic lysosomes in a nonenzymatic fashion (inhibited by bafilomycin A1, chloroquine, NH4Cl); phosphorylation of PC7 at Ser505 by Fam20C reduces apoA-V degradation. In Pcsk7-/- mice on high-fat diet, plasma apoA-V levels and adipocyte LPL activity are increased.","method":"Co-expression in HuH7 cells with bafilomycin A1/chloroquine/NH4Cl inhibition, PC7 phosphomimetic mutant (S505E) co-expression, Pcsk7-/- mouse model on HFD, adipocyte LPL activity measurement","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based binding and degradation assays with pharmacological inhibitors and phosphomimetic mutants, plus in vivo Pcsk7 KO validation, single lab","pmids":["31945259"],"is_preprint":false},{"year":2024,"finding":"ApoA5 deficiency in CRISPR/Cas9-edited hamsters causes hepatic steatosis associated with reduced NR1D1 mRNA stability and protein levels; AAV8-mediated overexpression of NR1D1 in ApoA5-/- hamster livers ameliorated fatty liver without correcting plasma lipid levels, indicating a direct hepatic role for ApoA5 in regulating NR1D1.","method":"CRISPR/Cas9 ApoA5-/- hamster model, HFD challenge, AAV8-NR1D1 liver overexpression, mRNA stability assay in HepG2 cells, UCP1 activation experiments","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with AAV rescue experiment, in vitro mechanistic follow-up, single lab","pmids":["38505614"],"is_preprint":false}],"current_model":"APOA5 encodes a liver-secreted apolipoprotein that lowers plasma triglycerides primarily by binding—via its C-terminal sequences—to the ANGPTL3/8 complex and suppressing its inhibition of lipoprotein lipase (LPL), thereby maintaining LPL activity and its anchoring within capillaries of oxidative tissues; additional mechanisms include reducing apoC-III content on VLDL to facilitate VLDL catabolism, modulating hepatic TG secretion and ectopic lipid deposition (influencing tissue insulin sensitivity), and being regulated transcriptionally by thyroid hormone/TR via a DR4 element and by CREBH in response to protein restriction, post-transcriptionally by miR-485-5p (through a 3'UTR variant), and post-translationally through PC7-mediated lysosomal degradation."},"narrative":{"mechanistic_narrative":"APOA5 encodes a liver-secreted apolipoprotein that lowers plasma triglycerides by sustaining lipoprotein lipase (LPL) activity within the capillaries of oxidative tissues [PMID:33762177, PMID:38880127]. Its central mechanism is binding the ANGPTL3/8 complex and suppressing ANGPTL3/8-mediated inhibition of LPL; apoA-V has no direct stimulatory effect on LPL and does not counteract ANGPTL3, ANGPTL4, or ANGPTL4/8 individually [PMID:33762177]. This activity is governed by the C-terminal ~35-40 residues, which are required to bind ANGPTL3/8, block ANGPTL3/8-driven detachment of LPL from capillary binding sites, and lower triglycerides in vivo, such that a C-terminal truncation mutant (APOA5Δ40) loses all of these functions [PMID:38625948]. Consistent with this, APOA5 deficiency increases ANGPTL3/8-mediated LPL detachment and depletes intracapillary LPL in heart and brown adipose tissue, defects rescued by recombinant APOA5 or by an ANGPTL3/8-specific antibody [PMID:38880127]. Beyond LPL anchoring, apoA-V reduces apoC-III content on VLDL to enhance VLDL catabolism [PMID:17438339], and binds LDL-family receptors LRP1, sortilin, and SorLA, with distinct missense and truncation variants separating LPL-activation from receptor-binding functions [PMID:18635818, PMID:23307945]. Naturally occurring variants establish causal genotype-phenotype links: S19W impairs signal-peptide-dependent secretion and lowers plasma apoA-V [PMID:15941721, PMID:17936576], the G185C variant introduces a free cysteine that forms aberrant disulfide bonds sequestering apoA-V from lipoproteins [PMID:25127531], and truncations such as Q139X impair VLDL catabolism in carriers [PMID:16200213]. APOA5 expression is transcriptionally controlled by thyroid hormone/TR via a DR4 element acting with USF1/USF2 [PMID:15941710] and by CREBH during dietary protein restriction [PMID:30385734], post-transcriptionally repressed by miR-485-5p through a 3'UTR variant [PMID:24387992], and post-translationally degraded via PC7-mediated lysosomal targeting [PMID:31945259].","teleology":[{"year":2005,"claim":"Establishing how a coding polymorphism alters apoA-V abundance addressed whether APOA5 sequence variation acts at the level of protein secretion.","evidence":"Signal-peptide modeling and SP-SEAP fusion secretion assays in HepG2 cells for the S19W variant","pmids":["15941721"],"confidence":"Medium","gaps":["In vitro secretion reduction not yet confirmed in vivo at this stage","Downstream effect on plasma triglycerides not directly measured"]},{"year":2005,"claim":"Defining the first transcriptional input identified how hepatic APOA5 expression is hormonally controlled.","evidence":"Luciferase reporter and promoter mutagenesis plus T3-treated/hypothyroid rat models mapping a DR4 element and USF1/USF2 synergy","pmids":["15941710"],"confidence":"Medium","gaps":["Physiological contribution of thyroid regulation to triglyceride control not quantified","Single lab"]},{"year":2005,"claim":"A human truncation pedigree tested whether loss of apoA-V function impairs lipolysis in vivo.","evidence":"Family study with apoB100 kinetics and postheparin LPL activity/mass measurement in Q139X carriers","pmids":["16200213"],"confidence":"Medium","gaps":["Molecular basis of impaired LPL activity not resolved","Truncated protein's altered lipoprotein association mechanistically undefined"]},{"year":2007,"claim":"An in vivo knock-in confirmed the S19W variant as the causal determinant of reduced plasma apoA-V.","evidence":"Single-copy haplotype insertion at the mouse Hprt locus comparing APOA5*1/*2/*3 plasma apoA-V","pmids":["17936576"],"confidence":"Medium","gaps":["Does not address triglyceride phenotype mechanism","APOA5*2 effect left unexplained at this stage"]},{"year":2007,"claim":"Defining apoA-V's effect on VLDL composition clarified a receptor/co-factor-independent route to enhanced catabolism.","evidence":"Adenoviral apoA-V gene transfer in APOC3 transgenic mice with lipoprotein fractionation, LCAT and cholesterol efflux assays","pmids":["17438339"],"confidence":"Medium","gaps":["Mechanism of apoC-III displacement not established","HDL maturation effects not linked to a defined receptor pathway"]},{"year":2008,"claim":"Variant panels separated apoA-V's LPL-activation function from its receptor-binding function.","evidence":"In vitro LPL activity assays with VLDL substrate and LR8/LRP1 binding assays for missense and truncation variants","pmids":["18635818"],"confidence":"Medium","gaps":["Structural basis of separable functions not defined","Physiological weight of receptor binding versus LPL activation unresolved"]},{"year":2013,"claim":"Mapping multiple disease mutations onto binding partners revealed several functional domains in apoA-V.","evidence":"Recombinant variant proteins assayed for LPL activation, liposome/heparin binding, and LRP1/sortilin/SorLA binding with structural modeling","pmids":["23307945"],"confidence":"Medium","gaps":["Relative in vivo importance of each domain not tested","Single lab"]},{"year":2014,"claim":"Identifying aberrant disulfide formation explained how the G185C variant inactivates apoA-V.","evidence":"AAV gene transfer in apoa5-/- mice, nonreducing immunoblot, and IP-LC/MS of human plasma identifying fibronectin and kininogen-1 partners","pmids":["25127531"],"confidence":"High","gaps":["Whether sequestration is reversible or therapeutically targetable unknown"]},{"year":2014,"claim":"A 3'UTR variant was shown to create a microRNA site, defining a post-transcriptional control mechanism.","evidence":"Luciferase reporter assays in HEK293T and HuH-7 cells with miR-485-5p co-transfection and inhibitor rescue","pmids":["24387992"],"confidence":"Medium","gaps":["Endogenous magnitude of miR-485-5p regulation in vivo not measured","Single lab"]},{"year":2014,"claim":"Linking apoA-V to tissue lipid uptake placed it in the pathway controlling diet-induced insulin resistance.","evidence":"ASO knockdown in high-fat-diet mice with hyperinsulinemic-euglycemic clamps and tissue DAG/PKC measurements","pmids":["25548259"],"confidence":"Medium","gaps":["Causality between apoA-V-driven TG delivery and PKC activation correlative","Single lab"]},{"year":2018,"claim":"Establishing CREBH as a regulator connected dietary protein status to APOA5-mediated VLDL clearance.","evidence":"Protein-free diet, Crebh-KO and mTORC1 gain-of-function mice, ASO knockdown, plus a human randomized trial","pmids":["30385734"],"confidence":"Medium","gaps":["Direct CREBH binding to the APOA5 promoter not shown here","Single lab"]},{"year":2020,"claim":"Identifying PC7-mediated lysosomal degradation defined a post-translational control point for apoA-V abundance.","evidence":"Co-expression in HuH7 cells with lysosomal inhibitors, a PC7 S505E phosphomimetic, and Pcsk7-/- HFD mice","pmids":["31945259"],"confidence":"Medium","gaps":["Nonenzymatic mechanism of degradation mechanistically unclear","Single lab"]},{"year":2021,"claim":"Discovering the ANGPTL3/8 interaction resolved the long-sought molecular mechanism of apoA-V's triglyceride-lowering action.","evidence":"IP-MS, biolayer interferometry, and LPL enzymatic/kinetic assays in human serum with positive and negative controls","pmids":["33762177"],"confidence":"High","gaps":["Structure of the apoA-V–ANGPTL3/8 complex not determined","Stoichiometry of binding not defined"]},{"year":2024,"claim":"Domain mapping and in vivo rescue established that apoA-V's C-terminus is necessary for ANGPTL3/8 binding and capillary LPL retention.","evidence":"Recombinant proteins, APOA5Δ40 truncation, Apoa5-/- mouse rescue, anti-C-terminal antibody blockade, and LPL detachment assays","pmids":["38625948"],"confidence":"High","gaps":["Atomic-level binding interface not solved","Whether C-terminus contacts ANGPTL3, ANGPTL8, or both unresolved"]},{"year":2024,"claim":"Tissue-level analysis confirmed that apoA-V maintains intracapillary LPL by preventing ANGPTL3/8-mediated detachment.","evidence":"Apoa5-/- mice with recombinant APOA5 and ANGPTL3/8 inhibitory antibody, plus cell-culture LPL detachment assays","pmids":["38880127"],"confidence":"High","gaps":["Tissue selectivity for oxidative organs not fully explained"]},{"year":2024,"claim":"A hepatocyte-intrinsic role emerged linking apoA-V to NR1D1 and hepatic steatosis independent of plasma lipids.","evidence":"CRISPR ApoA5-/- hamsters with AAV8-NR1D1 liver rescue and mRNA-stability assays in HepG2 cells","pmids":["38505614"],"confidence":"Medium","gaps":["Mechanism by which apoA-V stabilizes NR1D1 mRNA unknown","Intracellular versus secreted apoA-V pool responsible not distinguished"]},{"year":null,"claim":"The atomic structure of the apoA-V–ANGPTL3/8 complex and the mechanistic basis of apoA-V's intracellular/hepatic functions remain to be defined.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of the apoA-V–ANGPTL3/8 interface","Mechanism coupling secreted apoA-V to hepatic NR1D1 regulation unresolved","Stoichiometry and binding interface with LDL-family receptors undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[7]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[9,11]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,2,8]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,12]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[2,12]}],"complexes":[],"partners":["ANGPTL3","ANGPTL8","LPL","LRP1","SORT1","SORL1","APOC3","PCSK7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6Q788","full_name":"Apolipoprotein A-V","aliases":["Apolipoprotein A5","Regeneration-associated protein 3"],"length_aa":366,"mass_kda":41.2,"function":"Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin (PubMed:17326667)","subcellular_location":"Secreted; Early endosome; Late endosome; Golgi apparatus, trans-Golgi network","url":"https://www.uniprot.org/uniprotkb/Q6Q788/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA5","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA5","total_profiled":1310},"omim":[{"mim_id":"619324","title":"HYPERTRIGLYCERIDEMIA 2; HYTG2","url":"https://www.omim.org/entry/619324"},{"mim_id":"615947","title":"HYPERLIPOPROTEINEMIA, TYPE ID","url":"https://www.omim.org/entry/615947"},{"mim_id":"615385","title":"MICRO RNA 485; MIR485","url":"https://www.omim.org/entry/615385"},{"mim_id":"612757","title":"GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED HIGH DENSITY LIPOPROTEIN-BINDING PROTEIN 1; GPIHBP1","url":"https://www.omim.org/entry/612757"},{"mim_id":"606945","title":"LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR","url":"https://www.omim.org/entry/606945"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":568.8}],"url":"https://www.proteinatlas.org/search/APOA5"},"hgnc":{"alias_symbol":["RAP3","APOA-V"],"prev_symbol":[]},"alphafold":{"accession":"Q6Q788","domains":[{"cath_id":"1.20.120.20","chopping":"109-265_272-316","consensus_level":"medium","plddt":85.621,"start":109,"end":316}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6Q788","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6Q788-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6Q788-F1-predicted_aligned_error_v6.png","plddt_mean":71.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA5","jax_strain_url":"https://www.jax.org/strain/search?query=APOA5"},"sequence":{"accession":"Q6Q788","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6Q788.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6Q788/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6Q788"}},"corpus_meta":[{"pmid":"25487149","id":"PMC_25487149","title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25487149","citation_count":532,"is_preprint":false},{"pmid":"22239554","id":"PMC_22239554","title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.","date":"2012","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22239554","citation_count":204,"is_preprint":false},{"pmid":"15342688","id":"PMC_15342688","title":"Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15342688","citation_count":139,"is_preprint":false},{"pmid":"16200213","id":"PMC_16200213","title":"Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16200213","citation_count":130,"is_preprint":false},{"pmid":"12951359","id":"PMC_12951359","title":"The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12951359","citation_count":123,"is_preprint":false},{"pmid":"12697303","id":"PMC_12697303","title":"Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12697303","citation_count":105,"is_preprint":false},{"pmid":"12671030","id":"PMC_12671030","title":"Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12671030","citation_count":101,"is_preprint":false},{"pmid":"15941721","id":"PMC_15941721","title":"Determination of the functionality of common APOA5 polymorphisms.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15941721","citation_count":100,"is_preprint":false},{"pmid":"14729863","id":"PMC_14729863","title":"APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/14729863","citation_count":92,"is_preprint":false},{"pmid":"16531747","id":"PMC_16531747","title":"APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency.","date":"2006","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/16531747","citation_count":76,"is_preprint":false},{"pmid":"17211608","id":"PMC_17211608","title":"APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17211608","citation_count":74,"is_preprint":false},{"pmid":"12752569","id":"PMC_12752569","title":"APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men.","date":"2003","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12752569","citation_count":73,"is_preprint":false},{"pmid":"33762177","id":"PMC_33762177","title":"ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/33762177","citation_count":72,"is_preprint":false},{"pmid":"15306190","id":"PMC_15306190","title":"APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease.","date":"2004","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15306190","citation_count":66,"is_preprint":false},{"pmid":"16682041","id":"PMC_16682041","title":"The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16682041","citation_count":62,"is_preprint":false},{"pmid":"17768309","id":"PMC_17768309","title":"APOA5 variants and metabolic syndrome in Caucasians.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17768309","citation_count":61,"is_preprint":false},{"pmid":"25034063","id":"PMC_25034063","title":"A functional variant in APOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency.","date":"2014","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25034063","citation_count":58,"is_preprint":false},{"pmid":"23000317","id":"PMC_23000317","title":"The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.","date":"2012","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23000317","citation_count":57,"is_preprint":false},{"pmid":"21209257","id":"PMC_21209257","title":"APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population.","date":"2011","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/21209257","citation_count":56,"is_preprint":false},{"pmid":"28865324","id":"PMC_28865324","title":"The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke: Evidence from a meta-analysis.","date":"2017","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/28865324","citation_count":55,"is_preprint":false},{"pmid":"16474174","id":"PMC_16474174","title":"Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16474174","citation_count":55,"is_preprint":false},{"pmid":"16777114","id":"PMC_16777114","title":"Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16777114","citation_count":55,"is_preprint":false},{"pmid":"15941710","id":"PMC_15941710","title":"Thyroid hormone regulates the hypotriglyceridemic gene APOA5.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15941710","citation_count":54,"is_preprint":false},{"pmid":"26365669","id":"PMC_26365669","title":"Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects.","date":"2015","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26365669","citation_count":54,"is_preprint":false},{"pmid":"25548259","id":"PMC_25548259","title":"ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25548259","citation_count":52,"is_preprint":false},{"pmid":"24387992","id":"PMC_24387992","title":"An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.","date":"2014","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24387992","citation_count":52,"is_preprint":false},{"pmid":"18635818","id":"PMC_18635818","title":"Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding.","date":"2008","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18635818","citation_count":52,"is_preprint":false},{"pmid":"28500476","id":"PMC_28500476","title":"Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact.","date":"2017","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/28500476","citation_count":49,"is_preprint":false},{"pmid":"27827461","id":"PMC_27827461","title":"Association and interaction of APOA5, BUD13, CETP, LIPA and health-related behavior with metabolic syndrome in a Taiwanese population.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27827461","citation_count":49,"is_preprint":false},{"pmid":"18779834","id":"PMC_18779834","title":"APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia.","date":"2008","source":"Nature clinical practice. Cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18779834","citation_count":48,"is_preprint":false},{"pmid":"16861622","id":"PMC_16861622","title":"Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16861622","citation_count":48,"is_preprint":false},{"pmid":"15604515","id":"PMC_15604515","title":"APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15604515","citation_count":48,"is_preprint":false},{"pmid":"17438339","id":"PMC_17438339","title":"Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17438339","citation_count":47,"is_preprint":false},{"pmid":"19159622","id":"PMC_19159622","title":"The apolipoprotein A5 -1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease.","date":"2008","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19159622","citation_count":47,"is_preprint":false},{"pmid":"18324930","id":"PMC_18324930","title":"Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene.","date":"2008","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18324930","citation_count":46,"is_preprint":false},{"pmid":"22914552","id":"PMC_22914552","title":"APOA5 genotype modulates 2-y changes in lipid profile in response to weight-loss diet intervention: the Pounds Lost Trial.","date":"2012","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/22914552","citation_count":46,"is_preprint":false},{"pmid":"19056598","id":"PMC_19056598","title":"Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states.","date":"2008","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/19056598","citation_count":45,"is_preprint":false},{"pmid":"16321685","id":"PMC_16321685","title":"Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.","date":"2006","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/16321685","citation_count":44,"is_preprint":false},{"pmid":"21130994","id":"PMC_21130994","title":"Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21130994","citation_count":44,"is_preprint":false},{"pmid":"23468858","id":"PMC_23468858","title":"Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23468858","citation_count":41,"is_preprint":false},{"pmid":"16125709","id":"PMC_16125709","title":"SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population.","date":"2005","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16125709","citation_count":41,"is_preprint":false},{"pmid":"23307945","id":"PMC_23307945","title":"Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23307945","citation_count":41,"is_preprint":false},{"pmid":"17032446","id":"PMC_17032446","title":"Triglyceride associated polymorphisms of the APOA5 gene have very different allele frequencies in Pune, India compared to Europeans.","date":"2006","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17032446","citation_count":41,"is_preprint":false},{"pmid":"30385734","id":"PMC_30385734","title":"Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30385734","citation_count":39,"is_preprint":false},{"pmid":"19910639","id":"PMC_19910639","title":"Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19910639","citation_count":39,"is_preprint":false},{"pmid":"21889769","id":"PMC_21889769","title":"Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.","date":"2011","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21889769","citation_count":39,"is_preprint":false},{"pmid":"16887900","id":"PMC_16887900","title":"Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.","date":"2006","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16887900","citation_count":39,"is_preprint":false},{"pmid":"26824674","id":"PMC_26824674","title":"Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26824674","citation_count":34,"is_preprint":false},{"pmid":"18601598","id":"PMC_18601598","title":"Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults.","date":"2008","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18601598","citation_count":34,"is_preprint":false},{"pmid":"17197160","id":"PMC_17197160","title":"The effect of APOA5 and APOC3 variants on lipid parameters in European Whites, Indian Asians and Afro-Caribbeans with type 2 diabetes.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17197160","citation_count":33,"is_preprint":false},{"pmid":"17142127","id":"PMC_17142127","title":"Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study.","date":"2006","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/17142127","citation_count":31,"is_preprint":false},{"pmid":"18263854","id":"PMC_18263854","title":"Influence of apoA-V gene variants on postprandial triglyceride metabolism: impact of gender.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18263854","citation_count":30,"is_preprint":false},{"pmid":"17726453","id":"PMC_17726453","title":"Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.","date":"2007","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/17726453","citation_count":30,"is_preprint":false},{"pmid":"17222847","id":"PMC_17222847","title":"Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.","date":"2007","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17222847","citation_count":29,"is_preprint":false},{"pmid":"24903888","id":"PMC_24903888","title":"Triglyceride-raising APOA5 genetic variants are associated with obesity and non-HDL-C in Chinese children and adolescents.","date":"2014","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/24903888","citation_count":28,"is_preprint":false},{"pmid":"16143024","id":"PMC_16143024","title":"Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.","date":"2005","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16143024","citation_count":28,"is_preprint":false},{"pmid":"25770687","id":"PMC_25770687","title":"APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25770687","citation_count":27,"is_preprint":false},{"pmid":"19018513","id":"PMC_19018513","title":"The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits.","date":"2008","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/19018513","citation_count":27,"is_preprint":false},{"pmid":"24690159","id":"PMC_24690159","title":"Consumption of whole grains and legumes modulates the genetic effect of the APOA5 -1131C variant on changes in triglyceride and apolipoprotein A-V concentrations in patients with impaired fasting glucose or newly diagnosed type 2 diabetes.","date":"2014","source":"Trials","url":"https://pubmed.ncbi.nlm.nih.gov/24690159","citation_count":27,"is_preprint":false},{"pmid":"23656756","id":"PMC_23656756","title":"Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults.","date":"2013","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/23656756","citation_count":27,"is_preprint":false},{"pmid":"25308402","id":"PMC_25308402","title":"Association of USF1 and APOA5 polymorphisms with familial combined hyperlipidemia in an Italian population.","date":"2014","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/25308402","citation_count":25,"is_preprint":false},{"pmid":"22517333","id":"PMC_22517333","title":"Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study.","date":"2012","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/22517333","citation_count":25,"is_preprint":false},{"pmid":"16943456","id":"PMC_16943456","title":"Comparison of low-fat meal and high-fat meal on postprandial lipemic response in non-obese men according to the -1131T>C polymorphism of the apolipoprotein A5 (APOA5) gene (randomized cross-over design).","date":"2006","source":"Journal of the American College of Nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16943456","citation_count":25,"is_preprint":false},{"pmid":"21438666","id":"PMC_21438666","title":"Association of PON1 and APOA5 gene polymorphisms in a cohort of Indian patients having coronary artery disease with and without type 2 diabetes.","date":"2011","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/21438666","citation_count":24,"is_preprint":false},{"pmid":"24684850","id":"PMC_24684850","title":"Association of APOA5 rs662799 and rs3135506 polymorphisms with arterial hypertension in Moroccan patients.","date":"2014","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/24684850","citation_count":23,"is_preprint":false},{"pmid":"18468520","id":"PMC_18468520","title":"Association of APOA5 -1131T>C and S19W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients.","date":"2008","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18468520","citation_count":23,"is_preprint":false},{"pmid":"18537870","id":"PMC_18537870","title":"Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.","date":"2008","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18537870","citation_count":22,"is_preprint":false},{"pmid":"19447388","id":"PMC_19447388","title":"Modulation of phenotypic expression of APOA5 Q97X and L242P mutations.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19447388","citation_count":21,"is_preprint":false},{"pmid":"17936576","id":"PMC_17936576","title":"In vivo characterization of human APOA5 haplotypes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17936576","citation_count":21,"is_preprint":false},{"pmid":"20304614","id":"PMC_20304614","title":"The influence of the S19W SNP of the APOA5 gene on triglyceride levels in southern Brazil: interactions with the APOE gene, sex and menopause status.","date":"2010","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/20304614","citation_count":21,"is_preprint":false},{"pmid":"19344899","id":"PMC_19344899","title":"The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19344899","citation_count":21,"is_preprint":false},{"pmid":"20392444","id":"PMC_20392444","title":"APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/20392444","citation_count":20,"is_preprint":false},{"pmid":"26397108","id":"PMC_26397108","title":"Effects of Polymorphisms in APOA4-APOA5-ZNF259-BUD13 Gene Cluster on Plasma Levels of Triglycerides and Risk of Coronary Heart Disease in a Chinese Han Population.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26397108","citation_count":20,"is_preprint":false},{"pmid":"20571505","id":"PMC_20571505","title":"A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20571505","citation_count":20,"is_preprint":false},{"pmid":"29866721","id":"PMC_29866721","title":"Effects of polymorphisms in APOA5 on the plasma levels of triglycerides and risk of coronary heart disease in Jilin, northeast China: a case-control study.","date":"2018","source":"BMJ open","url":"https://pubmed.ncbi.nlm.nih.gov/29866721","citation_count":20,"is_preprint":false},{"pmid":"24979386","id":"PMC_24979386","title":"Rs964184 (APOA5-A4-C3-A1) is related to elevated plasma triglyceride levels, but not to an increased risk for vascular events in patients with clinically manifest vascular disease.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24979386","citation_count":20,"is_preprint":false},{"pmid":"18549811","id":"PMC_18549811","title":"Interaction between APOA5 -1131T>C and APOE polymorphisms and their association with severe hypertriglyceridemia.","date":"2008","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18549811","citation_count":19,"is_preprint":false},{"pmid":"19932084","id":"PMC_19932084","title":"Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19932084","citation_count":19,"is_preprint":false},{"pmid":"25313938","id":"PMC_25313938","title":"Influences of APOA5 variants on plasma triglyceride levels in Uyghur population.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25313938","citation_count":19,"is_preprint":false},{"pmid":"21993410","id":"PMC_21993410","title":"Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia.","date":"2011","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21993410","citation_count":19,"is_preprint":false},{"pmid":"25127531","id":"PMC_25127531","title":"Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291).","date":"2014","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25127531","citation_count":19,"is_preprint":false},{"pmid":"20688329","id":"PMC_20688329","title":"The apolipoprotein A5 (APOA5) gene predisposes Caucasian children to elevated triglycerides and vitamin E (Four Provinces Study).","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/20688329","citation_count":19,"is_preprint":false},{"pmid":"22425169","id":"PMC_22425169","title":"Vitamin D dependent effects of APOA5 polymorphisms on HDL cholesterol.","date":"2012","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/22425169","citation_count":19,"is_preprint":false},{"pmid":"18946207","id":"PMC_18946207","title":"Changes of plasma lipids during weight reduction in females depends on APOA5 variants.","date":"2008","source":"Annals of nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18946207","citation_count":19,"is_preprint":false},{"pmid":"31945259","id":"PMC_31945259","title":"Proprotein convertase 7 (PCSK7) reduces apoA-V levels.","date":"2020","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/31945259","citation_count":18,"is_preprint":false},{"pmid":"32561169","id":"PMC_32561169","title":"Gene-environment interaction between APOA5 c.553G>T and pregnancy in hypertriglyceridemia-induced acute pancreatitis.","date":"2020","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/32561169","citation_count":18,"is_preprint":false},{"pmid":"28376804","id":"PMC_28376804","title":"Estrogen lowers triglyceride via regulating hepatic APOA5 expression.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28376804","citation_count":18,"is_preprint":false},{"pmid":"27171122","id":"PMC_27171122","title":"APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children.","date":"2016","source":"Pediatric obesity","url":"https://pubmed.ncbi.nlm.nih.gov/27171122","citation_count":18,"is_preprint":false},{"pmid":"21846464","id":"PMC_21846464","title":"Two novel rare variants of APOA5 gene found in subjects with severe hypertriglyceridemia.","date":"2011","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21846464","citation_count":18,"is_preprint":false},{"pmid":"17157483","id":"PMC_17157483","title":"Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17157483","citation_count":18,"is_preprint":false},{"pmid":"24694356","id":"PMC_24694356","title":"Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24694356","citation_count":18,"is_preprint":false},{"pmid":"26345861","id":"PMC_26345861","title":"Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26345861","citation_count":17,"is_preprint":false},{"pmid":"38505614","id":"PMC_38505614","title":"Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38505614","citation_count":16,"is_preprint":false},{"pmid":"38880127","id":"PMC_38880127","title":"APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries.","date":"2024","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/38880127","citation_count":16,"is_preprint":false},{"pmid":"38625948","id":"PMC_38625948","title":"Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38625948","citation_count":15,"is_preprint":false},{"pmid":"31165758","id":"PMC_31165758","title":"Association of BUD13-ZNF259-APOA5-APOA1-SIK3 cluster polymorphism in 11q23.3 and structure of APOA5 with increased plasma triglyceride levels in a Korean population.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31165758","citation_count":15,"is_preprint":false},{"pmid":"29211729","id":"PMC_29211729","title":"A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29211729","citation_count":15,"is_preprint":false},{"pmid":"21548985","id":"PMC_21548985","title":"Relationship of APOA5, PPARγ and HL gene variants with serial changes in childhood body mass index and coronary artery disease risk factors in young adulthood.","date":"2011","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/21548985","citation_count":15,"is_preprint":false},{"pmid":"27613158","id":"PMC_27613158","title":"APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels.","date":"2016","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/27613158","citation_count":14,"is_preprint":false},{"pmid":"20054229","id":"PMC_20054229","title":"Gene-gene interaction between APOA5 and USF1: two candidate genes for the metabolic syndrome.","date":"2009","source":"Obesity facts","url":"https://pubmed.ncbi.nlm.nih.gov/20054229","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":60679,"output_tokens":4573,"usd":0.125316,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12513,"output_tokens":4524,"usd":0.087832,"stage2_stop_reason":"end_turn"},"total_usd":0.213148,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"ApoA5 lowers triglycerides by binding to the ANGPTL3/8 complex in human serum and suppressing ANGPTL3/8-mediated inhibition of lipoprotein lipase (LPL); ApoA5 has no direct stimulatory effect on LPL itself, nor does it suppress LPL inhibition by ANGPTL3, ANGPTL4, or ANGPTL4/8 alone.\",\n      \"method\": \"Immunoprecipitation-MS, Western blotting, biolayer interferometry, functional LPL enzymatic assays, kinetic analyses\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (IP-MS, biolayer interferometry, LPL activity assays) in a single rigorous study with both positive and negative controls; mechanistically conclusive\",\n      \"pmids\": [\"33762177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"APOA5 C-terminal sequences (last ~35-40 residues) are required for binding ANGPTL3/8, suppressing ANGPTL3/8-mediated inhibition of LPL catalytic activity, blocking ANGPTL3/8-mediated detachment of LPL from capillary binding sites, maintaining intracapillary LPL levels in oxidative tissues, and lowering plasma triglycerides in vivo; a truncation mutant lacking these residues (APOA5Δ40) fails at all these functions.\",\n      \"method\": \"Recombinant protein functional assays, LPL activity assays, Apoa5-/- mouse rescue experiments, anti-APOA5 C-terminal antibody injection in WT mice, cell culture LPL detachment assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal in vitro and in vivo experiments with domain-mapping mutagenesis (truncation mutant) and antibody blockade, replicated across cell and animal models\",\n      \"pmids\": [\"38625948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"APOA5 deficiency reduces amounts of LPL in capillaries of oxidative tissues (heart, brown adipose tissue) through increased ANGPTL3/8-mediated detachment of LPL from its binding sites; recombinant APOA5 normalizes both intracapillary LPL levels and plasma triglycerides in Apoa5-/- mice, and an ANGPTL3/8-specific inhibitory antibody phenocopies APOA5 function.\",\n      \"method\": \"Apoa5-/- mouse model, recombinant APOA5 administration, ANGPTL3/8 inhibitory antibody treatment, cell culture LPL binding/detachment assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo rescue experiments with recombinant protein plus mechanistic cell culture validation, consistent with PMID 38625948\",\n      \"pmids\": [\"38880127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The APOA5 S19W (c.56C>G) polymorphism impairs secretion of apoA-V: molecular modeling predicts increased membrane insertion angle for Trp-19 signal peptide, and an in vitro secretion assay using SP-SEAP fusion proteins in HepG2 cells showed ~50% reduction in secretion of the Trp-19 encoded signal peptide compared to Ser-19.\",\n      \"method\": \"Molecular modeling of signal peptide, SP-SEAP fusion protein secretion assay in HepG2 cells, in vitro transcription/translation assay, primer extension inhibition assay, luciferase reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro functional secretion assay with mechanistic modeling, single lab, but multiple complementary methods; in vivo validation later confirmed by PMID 17936576\",\n      \"pmids\": [\"15941721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The S19W (APOA5*3) haplotype-defining polymorphism is functionally responsible for reduced plasma apoA-V levels: knock-in of the single APOA5*3 allele (19W) at the mouse Hprt locus resulted in three-fold lower human plasma ApoA-V levels compared to common APOA5*1 haplotype, while APOA5*2 showed no difference in plasma apoA-V.\",\n      \"method\": \"Targeted single-copy haplotype insertion at Hprt locus in mice, plasma apoA-V measurement\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean in vivo knock-in experiment with precise genetic control, single lab, directly confirms S19W as causative functional variant\",\n      \"pmids\": [\"17936576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"APOA5 Q139X truncation mutation impairs VLDL catabolism and reduces lipoprotein lipase activity and mass in carriers; the truncated apoA-V protein shows altered association with plasma lipoprotein fractions compared to wild-type apoA-V. APOB100 kinetic studies revealed major impairment of VLDL catabolism in dyslipidemic Q139X carriers.\",\n      \"method\": \"Family/pedigree study, ultracentrifugation lipoprotein fractionation, APOB100 kinetic studies, postheparin LPL activity and mass measurement\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo human kinetic studies with multiple complementary measurements; mechanistically links APOA5 truncation to defective lipolysis\",\n      \"pmids\": [\"16200213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Specific APOA5 missense variants (E255G, G185C, H321L) reduce LPL activation using VLDL as substrate in vitro (by 23-36%), while truncation variants (Q139X, Q148X) and G271C show no significant reduction in LPL activity but abolish binding to LDL-family receptors LR8 and LRP1.\",\n      \"method\": \"In vitro LPL activity assay using VLDL substrate, receptor-binding assay to LR8 and LRP1 with recombinant apoA-V variants\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple defined mutants, single lab, demonstrates separable LPL-activation and receptor-binding functions\",\n      \"pmids\": [\"18635818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Three APOA5 mutations [p.(Ser232_Leu235)del, p.Leu253Pro, p.Asp332ValfsX4] impair LPL activation in vitro; recombinant mutant apoA-V variants show defective interactions with liposomes, heparin, LRP1, sortilin, and SorLA/LR11 compared to wild-type, indicating multiple functional domains are affected.\",\n      \"method\": \"Recombinant protein expression and purification, LPL activation assay, liposome binding, heparin binding, LRP1/sortilin/SorLA receptor binding assays, 3D structural modeling\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple orthogonal binding and activity assays, single lab\",\n      \"pmids\": [\"23307945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The APOA5 c.553G>T (rs2075291, p.Gly185Cys) variant introduces a free cysteine that forms aberrant hetero-disulfide bonds with plasma proteins (fibronectin, kininogen-1, and others), sequestering >50% of G162C apoA-V in the lipoprotein-free fraction and compromising its lipoprotein-binding and triglyceride-modulating functions.\",\n      \"method\": \"AAV2/8-mediated gene transfer in apoa5-/- mice, plasma fractionation, nonreducing SDS-PAGE immunoblot, immunoprecipitation followed by LC/MS of human plasma from homozygous subjects\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo gene transfer rescue, biochemical fractionation, mass spectrometry identification of aberrant disulfide partners in both mouse model and human plasma; multiple orthogonal methods\",\n      \"pmids\": [\"25127531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Thyroid hormone T3 directly regulates APOA5 expression in hepatocytes via a DR4 thyroid hormone response element in the APOA5 promoter; T3-activated thyroid receptor (TR) acts synergistically with USF1 and USF2 via an adjacent E-box motif to activate APOA5 promoter in a ligand-dependent manner.\",\n      \"method\": \"Luciferase reporter assays in hepatocytes, APOA5 mRNA/protein measurement in T3-treated and hypothyroid rats, TRbeta-selective agonist treatment, promoter deletion/mutation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct promoter functional assay with in vivo validation in rat model, single lab, multiple methods\",\n      \"pmids\": [\"15941710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The APOA5 3'UTR variant c.*158C (rs2266788) creates a functional binding site for liver-expressed miR-485-5p, leading to post-transcriptional downregulation of APOA5 mRNA; reporter assays and miR-485-5p inhibitor rescue confirmed this mechanism as a basis for the hypertriglyceridemic effect of the APOA5*2 haplotype.\",\n      \"method\": \"Luciferase reporter assay with APOA5 3'UTR in HEK293T and HuH-7 cells, miR-485-5p precursor co-transfection, miR-485-5p inhibitor rescue experiment, bioinformatics\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assay with inhibitor rescue in two cell lines, single lab, mechanistically specific\",\n      \"pmids\": [\"24387992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"APOA5 expression is regulated by the transcription factor CREBH in response to dietary protein restriction; PR stimulates VLDL-TG clearance by increasing VLDL-bound APOA5 expression, an effect abrogated by constitutive hepatic mTORC1 activation. This CREBH-APOA5 axis was conserved in a human clinical trial showing reduced VLDL particle number and increased VLDL-bound APOA5 upon protein restriction.\",\n      \"method\": \"Protein-free diet mouse model, Crebh-knockout mice, mTORC1 gain-of-function mice, ASO-mediated knockdown, VLDL-TG clearance assays, randomized controlled clinical trial\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with Crebh KO and mTORC1 GOF mice plus human translational validation, single lab\",\n      \"pmids\": [\"30385734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ApoA-V reduces apoC-III content in VLDL, resulting in enhanced VLDL catabolism without altering VLDL production; apoA-V also enriches HDL with apoA-I and apoE, enhances LCAT activity, and increases cholesterol efflux, promoting HDL maturation in APOC3 transgenic mice.\",\n      \"method\": \"Adenovirus-mediated apoA-V gene transfer into APOC3 transgenic mice, plasma TG/cholesterol measurement, lipoprotein fractionation, LCAT activity assay, cholesterol efflux assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gene transfer with multiple functional readouts in a defined transgenic model, single lab\",\n      \"pmids\": [\"17438339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ApoA5 knockdown in high-fat-diet mice (via ASO reducing hepatic ApoA5 by 60-70%) reduces TG uptake in liver and skeletal muscle, decreasing diacylglycerol content and DAG-mediated activation of PKCε (liver) and PKCθ (muscle), thereby protecting against diet-induced insulin resistance as assessed by hyperinsulinemic-euglycemic clamps.\",\n      \"method\": \"Antisense oligonucleotide knockdown in mice, VLDL-TG clearance assays, hyperinsulinemic-euglycemic clamp, PKC activity measurement, AKT2 phosphorylation assay, tissue TG/DAG measurement\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic KD with multiple mechanistic readouts in vivo, single lab, novel pathway placement\",\n      \"pmids\": [\"25548259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Proprotein convertase PC7 (PCSK7) binds to apoA-V and promotes its degradation in acidic lysosomes in a nonenzymatic fashion (inhibited by bafilomycin A1, chloroquine, NH4Cl); phosphorylation of PC7 at Ser505 by Fam20C reduces apoA-V degradation. In Pcsk7-/- mice on high-fat diet, plasma apoA-V levels and adipocyte LPL activity are increased.\",\n      \"method\": \"Co-expression in HuH7 cells with bafilomycin A1/chloroquine/NH4Cl inhibition, PC7 phosphomimetic mutant (S505E) co-expression, Pcsk7-/- mouse model on HFD, adipocyte LPL activity measurement\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based binding and degradation assays with pharmacological inhibitors and phosphomimetic mutants, plus in vivo Pcsk7 KO validation, single lab\",\n      \"pmids\": [\"31945259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ApoA5 deficiency in CRISPR/Cas9-edited hamsters causes hepatic steatosis associated with reduced NR1D1 mRNA stability and protein levels; AAV8-mediated overexpression of NR1D1 in ApoA5-/- hamster livers ameliorated fatty liver without correcting plasma lipid levels, indicating a direct hepatic role for ApoA5 in regulating NR1D1.\",\n      \"method\": \"CRISPR/Cas9 ApoA5-/- hamster model, HFD challenge, AAV8-NR1D1 liver overexpression, mRNA stability assay in HepG2 cells, UCP1 activation experiments\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with AAV rescue experiment, in vitro mechanistic follow-up, single lab\",\n      \"pmids\": [\"38505614\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA5 encodes a liver-secreted apolipoprotein that lowers plasma triglycerides primarily by binding—via its C-terminal sequences—to the ANGPTL3/8 complex and suppressing its inhibition of lipoprotein lipase (LPL), thereby maintaining LPL activity and its anchoring within capillaries of oxidative tissues; additional mechanisms include reducing apoC-III content on VLDL to facilitate VLDL catabolism, modulating hepatic TG secretion and ectopic lipid deposition (influencing tissue insulin sensitivity), and being regulated transcriptionally by thyroid hormone/TR via a DR4 element and by CREBH in response to protein restriction, post-transcriptionally by miR-485-5p (through a 3'UTR variant), and post-translationally through PC7-mediated lysosomal degradation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"APOA5 encodes a liver-secreted apolipoprotein that lowers plasma triglycerides by sustaining lipoprotein lipase (LPL) activity within the capillaries of oxidative tissues [#0, #2]. Its central mechanism is binding the ANGPTL3/8 complex and suppressing ANGPTL3/8-mediated inhibition of LPL; apoA-V has no direct stimulatory effect on LPL and does not counteract ANGPTL3, ANGPTL4, or ANGPTL4/8 individually [#0]. This activity is governed by the C-terminal ~35-40 residues, which are required to bind ANGPTL3/8, block ANGPTL3/8-driven detachment of LPL from capillary binding sites, and lower triglycerides in vivo, such that a C-terminal truncation mutant (APOA5\\u039440) loses all of these functions [#1]. Consistent with this, APOA5 deficiency increases ANGPTL3/8-mediated LPL detachment and depletes intracapillary LPL in heart and brown adipose tissue, defects rescued by recombinant APOA5 or by an ANGPTL3/8-specific antibody [#2]. Beyond LPL anchoring, apoA-V reduces apoC-III content on VLDL to enhance VLDL catabolism [#12], and binds LDL-family receptors LRP1, sortilin, and SorLA, with distinct missense and truncation variants separating LPL-activation from receptor-binding functions [#6, #7]. Naturally occurring variants establish causal genotype-phenotype links: S19W impairs signal-peptide-dependent secretion and lowers plasma apoA-V [#3, #4], the G185C variant introduces a free cysteine that forms aberrant disulfide bonds sequestering apoA-V from lipoproteins [#8], and truncations such as Q139X impair VLDL catabolism in carriers [#5]. APOA5 expression is transcriptionally controlled by thyroid hormone/TR via a DR4 element acting with USF1/USF2 [#9] and by CREBH during dietary protein restriction [#11], post-transcriptionally repressed by miR-485-5p through a 3'UTR variant [#10], and post-translationally degraded via PC7-mediated lysosomal targeting [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing how a coding polymorphism alters apoA-V abundance addressed whether APOA5 sequence variation acts at the level of protein secretion.\",\n      \"evidence\": \"Signal-peptide modeling and SP-SEAP fusion secretion assays in HepG2 cells for the S19W variant\",\n      \"pmids\": [\"15941721\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro secretion reduction not yet confirmed in vivo at this stage\", \"Downstream effect on plasma triglycerides not directly measured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defining the first transcriptional input identified how hepatic APOA5 expression is hormonally controlled.\",\n      \"evidence\": \"Luciferase reporter and promoter mutagenesis plus T3-treated/hypothyroid rat models mapping a DR4 element and USF1/USF2 synergy\",\n      \"pmids\": [\"15941710\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contribution of thyroid regulation to triglyceride control not quantified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"A human truncation pedigree tested whether loss of apoA-V function impairs lipolysis in vivo.\",\n      \"evidence\": \"Family study with apoB100 kinetics and postheparin LPL activity/mass measurement in Q139X carriers\",\n      \"pmids\": [\"16200213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of impaired LPL activity not resolved\", \"Truncated protein's altered lipoprotein association mechanistically undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"An in vivo knock-in confirmed the S19W variant as the causal determinant of reduced plasma apoA-V.\",\n      \"evidence\": \"Single-copy haplotype insertion at the mouse Hprt locus comparing APOA5*1/*2/*3 plasma apoA-V\",\n      \"pmids\": [\"17936576\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not address triglyceride phenotype mechanism\", \"APOA5*2 effect left unexplained at this stage\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defining apoA-V's effect on VLDL composition clarified a receptor/co-factor-independent route to enhanced catabolism.\",\n      \"evidence\": \"Adenoviral apoA-V gene transfer in APOC3 transgenic mice with lipoprotein fractionation, LCAT and cholesterol efflux assays\",\n      \"pmids\": [\"17438339\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of apoC-III displacement not established\", \"HDL maturation effects not linked to a defined receptor pathway\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Variant panels separated apoA-V's LPL-activation function from its receptor-binding function.\",\n      \"evidence\": \"In vitro LPL activity assays with VLDL substrate and LR8/LRP1 binding assays for missense and truncation variants\",\n      \"pmids\": [\"18635818\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of separable functions not defined\", \"Physiological weight of receptor binding versus LPL activation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mapping multiple disease mutations onto binding partners revealed several functional domains in apoA-V.\",\n      \"evidence\": \"Recombinant variant proteins assayed for LPL activation, liposome/heparin binding, and LRP1/sortilin/SorLA binding with structural modeling\",\n      \"pmids\": [\"23307945\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative in vivo importance of each domain not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying aberrant disulfide formation explained how the G185C variant inactivates apoA-V.\",\n      \"evidence\": \"AAV gene transfer in apoa5-/- mice, nonreducing immunoblot, and IP-LC/MS of human plasma identifying fibronectin and kininogen-1 partners\",\n      \"pmids\": [\"25127531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether sequestration is reversible or therapeutically targetable unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A 3'UTR variant was shown to create a microRNA site, defining a post-transcriptional control mechanism.\",\n      \"evidence\": \"Luciferase reporter assays in HEK293T and HuH-7 cells with miR-485-5p co-transfection and inhibitor rescue\",\n      \"pmids\": [\"24387992\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous magnitude of miR-485-5p regulation in vivo not measured\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linking apoA-V to tissue lipid uptake placed it in the pathway controlling diet-induced insulin resistance.\",\n      \"evidence\": \"ASO knockdown in high-fat-diet mice with hyperinsulinemic-euglycemic clamps and tissue DAG/PKC measurements\",\n      \"pmids\": [\"25548259\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality between apoA-V-driven TG delivery and PKC activation correlative\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Establishing CREBH as a regulator connected dietary protein status to APOA5-mediated VLDL clearance.\",\n      \"evidence\": \"Protein-free diet, Crebh-KO and mTORC1 gain-of-function mice, ASO knockdown, plus a human randomized trial\",\n      \"pmids\": [\"30385734\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CREBH binding to the APOA5 promoter not shown here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying PC7-mediated lysosomal degradation defined a post-translational control point for apoA-V abundance.\",\n      \"evidence\": \"Co-expression in HuH7 cells with lysosomal inhibitors, a PC7 S505E phosphomimetic, and Pcsk7-/- HFD mice\",\n      \"pmids\": [\"31945259\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nonenzymatic mechanism of degradation mechanistically unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovering the ANGPTL3/8 interaction resolved the long-sought molecular mechanism of apoA-V's triglyceride-lowering action.\",\n      \"evidence\": \"IP-MS, biolayer interferometry, and LPL enzymatic/kinetic assays in human serum with positive and negative controls\",\n      \"pmids\": [\"33762177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the apoA-V\\u2013ANGPTL3/8 complex not determined\", \"Stoichiometry of binding not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Domain mapping and in vivo rescue established that apoA-V's C-terminus is necessary for ANGPTL3/8 binding and capillary LPL retention.\",\n      \"evidence\": \"Recombinant proteins, APOA5\\u039440 truncation, Apoa5-/- mouse rescue, anti-C-terminal antibody blockade, and LPL detachment assays\",\n      \"pmids\": [\"38625948\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-level binding interface not solved\", \"Whether C-terminus contacts ANGPTL3, ANGPTL8, or both unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Tissue-level analysis confirmed that apoA-V maintains intracapillary LPL by preventing ANGPTL3/8-mediated detachment.\",\n      \"evidence\": \"Apoa5-/- mice with recombinant APOA5 and ANGPTL3/8 inhibitory antibody, plus cell-culture LPL detachment assays\",\n      \"pmids\": [\"38880127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue selectivity for oxidative organs not fully explained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A hepatocyte-intrinsic role emerged linking apoA-V to NR1D1 and hepatic steatosis independent of plasma lipids.\",\n      \"evidence\": \"CRISPR ApoA5-/- hamsters with AAV8-NR1D1 liver rescue and mRNA-stability assays in HepG2 cells\",\n      \"pmids\": [\"38505614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which apoA-V stabilizes NR1D1 mRNA unknown\", \"Intracellular versus secreted apoA-V pool responsible not distinguished\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The atomic structure of the apoA-V\\u2013ANGPTL3/8 complex and the mechanistic basis of apoA-V's intracellular/hepatic functions remain to be defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of the apoA-V\\u2013ANGPTL3/8 interface\", \"Mechanism coupling secreted apoA-V to hepatic NR1D1 regulation unresolved\", \"Stoichiometry and binding interface with LDL-family receptors undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [9, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 12]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [2, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ANGPTL3\", \"ANGPTL8\", \"LPL\", \"LRP1\", \"SORT1\", \"SORL1\", \"APOC3\", \"PCSK7\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}